🇺🇸 FDA
Patent

US 7375079

Previns as specific inhibitors and therapeutic agents for botulinum toxin B and tetanus neurotoxins

granted A61KA61K38/00A61P

Quick answer

US patent 7375079 (Previns as specific inhibitors and therapeutic agents for botulinum toxin B and tetanus neurotoxins) held by The United States of America as represented by the Secretary of the Army expires Mon May 15 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as represented by the Secretary of the Army
Grant date
Tue May 20 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 15 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K38/00, A61P, A61P31/04, A61P39/02